Annual report pursuant to Section 13 and 15(d)

Royalty and Commercial Payment Purchase Agreements - Agenus (Details)

v3.22.0.1
Royalty and Commercial Payment Purchase Agreements - Agenus (Details)
$ in Thousands
 1 Months Ended 12 Months Ended
Sep. 20, 2018
USD ($)
product
Nov. 30, 2020
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Agreements          
Payments related to purchase of royalty rights and other commercial payment rights     $ 26,500 $ 1,200  
Long-term royalty and commercial payment receivables     69,075 34,575 $ 34,375
Revenue from contracts with customers     36,518 27,941  
Impairment of long-term royalty receivable     0 0  
Royalty Purchase Agreement | Merck Immuno-Oncology Product | Agenus [Member]          
Agreements          
Amount of milestone achieved   $ 10,000      
Agenus [Member]          
Agreements          
Cash receipts for achievement of contractual milestones       $ 1,000  
Agenus [Member] | Royalty Purchase Agreement          
Agreements          
Payments related to purchase of royalty rights and other commercial payment rights $ 15,000        
Long-term royalty and commercial payment receivables $ 15,000        
Impairment of long-term royalty receivable     $ 0    
Agenus [Member] | Royalty Purchase Agreement | Incyte Immuno-Oncology Assets          
Agreements          
Royalties entity has right to receive (as a percent) 33.00%        
Number of licensed products related to milestone and royalties | product 6        
Purchased percentage of milestones 10.00%        
Agenus [Member] | Royalty Purchase Agreement | Merck Immuno-Oncology Product          
Agreements          
Royalties entity has right to receive (as a percent) 33.00%        
Purchased percentage of milestones 10.00%        
Purchased eligible milestone payments receivable upon achievement of potential development, regulatory and commercial milestones $ 59,500        
Amount of milestone achieved   1,000      
Cash receipts for achievement of contractual milestones   $ 1,000